| 摘要 |
The present invention relates to novel mutants of Streptokinase, its functional fragments and covalently modified forms. Methods are provided for the preparation of the bacterial plasminogen activator protein, Streptokinase its muteins, species variants and their covalently modified variants that are characterized by improved therapeutic properties, such as increased proteolytic stability, extended plasma half-lives, reduced immuno-reactivity and enhanced fibrin clot specificity. The method involves either incorporating additional cysteine residues, or substituting cysteine residues for naturally occurring amino acids into non-essential regions of the protein such that the catalytic activity of the resultant protein remains largely unaltered. These cysteine variants were further modified by covalently attaching a cysteine reactive polymer such as polyethylene glycol (PEG) or sulfhydryl-reactive moieties from a group that includes fluorophore, spin labels or other small conjugates. Disclosed herein are site-specific biologically active conjugates of Streptokinases and its covalently modified variants. |
| 主权项 |
1. A mutant streptokinase polypeptide comprising substitution of one to six amino acid residues of SEQ ID NO: 1, wherein the amino acid residue substituted with said cysteine residue is selected from the group consisting of G49, S57, A64, 188, S93, D95, D96, D102, S105, D120, K121, D122, E148, K156, D173, D174, L179, D181, 5205, A251, 1254, N255, K256, K257, 5258, L260, E281, K282, F287, D303, L321, L326, A333, D347, D360 and R372. |
